Venetoclax is a B cell lymphoma-2 (BCL-2) inhibitor used to treat various types of leukemia and is but actively being investigated as a potential treatment for DLBCL due to the role of BCL-2 in this malignancy. Here, BCL2 is linked to diffuse large B-cell lymphoma.